roferon a 3 mui 05 ml solução injetável - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

roferon-a

roche products (nz) ltd - interferon alfa-2a 6 miu/ml; - solution for injection - 3miu/0.5ml - active: interferon alfa-2a 6 miu/ml excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

New Zealand - English - Medsafe (Medicines Safety Authority)

roferon-a

roche products (nz) ltd - interferon alfa-2a 12 miu/ml; - solution for injection - 6miu/0.5ml - active: interferon alfa-2a 12 miu/ml excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

New Zealand - English - Medsafe (Medicines Safety Authority)

roferon-a

roche products (nz) ltd - interferon alfa-2a 18 miu/ml; - solution for injection - 9miu/0.5ml - active: interferon alfa-2a 18 miu/ml excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).